Back to Stakeholders
Research, Drug Development & ManufacturingLead program: Pre-clinical

Mydecine InnovationsNEO: MYCO

4 Drug Candidates

Canadian biotech using AI-assisted drug discovery at the University of Alberta to develop novel psilocybin and MDMA analogues for mental health and addiction treatment. Pipeline compounds MYCO-003 through MYCO-007 represent a library of psychedelic-inspired molecules at preclinical stage.

Drug Pipeline

4

MYCO-003

Psilocybin
Pre-clinical

Novel psilocybin analogue from AI-assisted medicinal chemistry programme at the University of Alberta.

MYCO-005

MDMA
Pre-clinical

Novel MDMA analogue designed for improved safety profile and therapeutic window.

MYCO-006

Pre-clinical

Psychedelic-inspired small molecule from AI-driven discovery pipeline.

MYCO-007

Pre-clinical

Psychedelic-inspired small molecule from AI-driven discovery pipeline.

Quick Facts

Type
Public Biotech
Ticker
NEO: MYCO
Lead Stage
Pre-clinical
Website
Visit